Tag Archives: pharmaceutical consultancy

Clinical trials in Australia: where sponsor teams need support most

Image
Image

Australia continues to attract attention as a destination for early-phase and sponsor-led studies.

The reasons are well understood. Faster start-up, a strong clinical research environment and a more efficient pathway into early development all make Australia commercially and operationally attractive.

But choosing Australia is not the same as being ready to run well in Australia.

For many lean sponsor teams, the real challenge starts once a study moves from planning into delivery. That is the point where local oversight, safety governance, medical decision-making and operational responsiveness begin to matter in a much more practical way.

Why Australia remains attractive for sponsors

Australia remains attractive for a number of practical reasons.

For early-phase and exploratory studies, it offers a combination of speed, regulatory clarity and high-quality research infrastructure that is hard to ignore. For biotech teams working with limited internal resource, it can provide a more efficient route into clinical development than many other markets.

That is why Australia is often seen as a smart strategic choice, particularly for sponsors looking to move quickly without compromising study quality.

But the sponsors that tend to do this well are usually the ones that recognise local execution still depends on the right medical and operational support being in place from the outset.

In practice, three factors continue to make Australia especially attractive:

  • faster study start-up timelines
  • a clear and efficient early-phase pathway
  • strong research capability and high-quality sites

What lean sponsor teams tend to underestimate

In early planning, a study can look relatively manageable on paper.

In practice, once recruitment starts, safety data begins to accumulate and protocol decisions need to be made in real time, the pressure on a lean sponsor structure increases quickly.

For many teams, the challenge is not scientific capability. It is access to experienced medical support at the point where decisions need to be made quickly and confidently.

That usually shows up in familiar areas:

  • medical monitoring and safety review
  • protocol deviation and eligibility assessment
  • investigator support
  • dose escalation and safety governance
  • continuity across local and global teams

This is often the point where a study starts to feel more operationally demanding than expected.

Where sponsor teams usually need support first

Medical monitoring and safety oversight

Once a study is live, timely physician-led review becomes essential. Safety signals, adverse events, eligibility questions and protocol issues all need prompt assessment, particularly in early-phase settings where decision-making can directly affect study progression.

Dose escalation and governance

In first-in-human and dose-escalation studies, the quality of safety review and committee preparation can materially affect both confidence and pace. This is one of the areas where experienced external medical support can add immediate value.

Sponsor-side medical leadership

Lean biotech teams often do not need to build a large permanent structure. What they do need is senior medical input that can act as an extension of the sponsor team, support the CRO and provide oversight as complexity increases.

Regional coordination

Even where Australia is the initial market, studies rarely stay operationally simple for long. As programmes evolve, sponsors often need local and regional medical input that can support continuity without slowing the model down.

What this looks like in practice

We have supported sponsor teams across early-phase and global studies where medical oversight needed to be strengthened without building a large internal infrastructure.

That has included physician-led support through dose escalation and safety governance in first-in-human oncology, sponsor-side medical leadership for lean clinical-stage biotech teams and high-volume medical monitoring across complex multi-country programmes.

For sponsors considering Australia, the requirement is often similar: experienced medical support that can integrate quickly, support decision-making and maintain continuity as programme complexity increases.

“One of the best SRC meetings I have experienced in terms of preparation and execution.” Chief Medical Officer, oncology biotech sponsor

How MMD supports sponsor teams

My Medical Department supports clinical development with physician-led medical expertise across early and late-phase studies.

That includes:

  • medical monitoring
  • safety governance
  • dose escalation support
  • protocol and eligibility review
  • investigator support
  • sponsor-side medical leadership
  • medical writing and study documentation
  • continuity across global and regional delivery

For lean biotech and sponsor teams, that means access to experienced medical support without needing to build permanent infrastructure before it is truly needed.

Image

Where to find us in June

MMD will be at ARCS Australia 2026 from 10–12 June at ICC Sydney, where we will be at Booth 55 and are proud to be sponsoring the conference photo wall.

If you are attending and would like to compare notes on Australian clinical trials, medical monitoring or sponsor-side medical support, please reach out to our team in advance at enquiries@mymedicaldepartment.com to arrange a meeting.

A final thought

Australia may offer an attractive route into early clinical development, but successful delivery still depends on how well the study is supported once it starts moving.

The sponsors that navigate this best are not always the ones with the biggest internal teams.

They are usually the ones that recognise early where experienced medical oversight will make the greatest difference and build that support in before timelines become fragile.

If you are planning or running a study in Australia and would like to sense-check where support is likely to matter most, please contact us at enquiries@mymedicaldepartment.com.

Where Pharmaceutical Programmes Start to Slow Down

Mmd Hero Banner (1)
Executive Briefing · March 2026

Where Pharmaceutical Programmes Start to Slow Down

Across clinical development, medical affairs and global programme delivery, one issue is showing up more consistently right now. It is rarely a lack of expertise. More often, it is a lack of alignment — and by the time it becomes visible, it is usually already affecting timelines.

Clinical, medical, regulatory and commercial teams can all be doing strong work individually and still create delay collectively. Not because people are underperforming, but because they are moving at different speeds, under different pressures and without enough structural overlap to catch the gaps before they become bottlenecks.

“The bottleneck is not capability. It is the moment when throughput increases but capacity does not adjust in the same way.”

That usually becomes visible at predictable pressure points — conference periods, team transitions, key milestones, holiday cover and launch preparation. By the time the problem is obvious, it is often already affecting timelines.

Why Australia Is Becoming a Stronger Option for Early-Phase Trials

One of the clearest shifts we are seeing is the continued growth of early-phase and exploratory trial activity in Australia. The reasons are practical.

Speed

Study start-up can be faster than in the US and much of Europe

Regulatory clarity

The regulatory pathway is well understood, particularly for Phase I and II

Cost efficiency

The cost profile can be attractive, particularly in earlier development phases

Site quality

Strong site and investigator capability across the country

From a development strategy perspective, the case is clear. The part that is easier to underestimate is the operating model around it.

Once programmes are spread across regions, time zones and governance frameworks, execution becomes more demanding. The strategic decision may be sound, but the supporting structure does not always evolve at the same pace. That is often where delay begins.

Considering Australia for your next early-phase programme? We work with sponsors navigating this exact challenge across clinical development and regulatory strategy.

Talk to our team about your programme →

Where Bottlenecks Usually Appear in Clinical and Medical Affairs Teams

There are three places where we see this most consistently.

1. Medical Affairs and MLR Review

During high-volume periods, review processes come under pressure quickly. Materials arrive not fully ready. Signatory responsibility is concentrated in too few people. Workflows begin to fragment.

The result is predictable — delays increase, timelines become less reliable and pressure builds between teams at exactly the point when speed matters most.

2. Clinical Development and Medical Monitoring

As programmes scale, safety data is generated continuously. Oversight structures do not always scale with it. Signal interpretation slows. Escalation pathways become less clear across regions. Decision-making latency starts to creep in.

This is rarely dramatic at first. It is usually gradual — but it becomes very obvious once the programme is under pressure.

3. Global and Local Execution

As soon as work needs to move across markets, global strategy has to stay aligned with local requirements, local codes and local expectations. If that alignment is weak, teams end up dealing with inconsistent interpretation, slower approvals and avoidable compliance risk.

Zero

substantiated code complaints relating to MMD-approved materials in over 12 years. Compliance is not a constraint on speed — it is a condition for it.

What High-Performing Pharmaceutical Teams Do Differently

The strongest teams do not simply add more people when pressure appears. They make structural adjustments earlier.

  • Scaling review and signatory capacity before peak periods rather than during them
  • Embedding medical input earlier so materials arrive for review genuinely ready
  • Ensuring medical monitoring models keep pace with data flow rather than lagging behind it
  • Aligning global and local regulatory thinking before regional differences become execution blockers

In other words, they do not wait for friction to become visible before addressing it.

Early Warning Signs of a Misaligned Programme

A Quick Check

If any of these sound familiar, it is usually a sign that alignment is starting to break down — and worth addressing before timelines tighten further:

  • Review timelines are becoming less predictable
  • Increasing back-and-forth between medical and marketing teams
  • Materials requiring multiple review cycles before reaching approval
  • Delays linked to limited signatory or senior medical capacity
  • Bottlenecks appearing during periods that should have been manageable

These issues rarely resolve themselves. They tend to compound as timelines tighten.

“Since partnering with MMD we have found that our materials no longer reach a bottleneck in the copy process. I would recommend them as an agency for companies looking for effective and proactive solution providers.”

Dr Tim Patel

Medical Director UK, Astellas

How My Medical Department Supports Global Programmes

My Medical Department is a physician-led global medical consultancy supporting pharmaceutical and biotech organisations across clinical development, medical affairs and regulatory strategy. Our teams are based in Australia, the UK and Latin America, with project support delivered globally.

We are currently supporting organisations with:

  • Managing peak MLR review demand and signatory capacity
  • Implementing continuous medical monitoring in clinical programmes
  • Strengthening global-to-local regulatory alignment across regions
  • Strategic consultancy across clinical development, medical affairs and market access
Australia United Kingdom Latin America

Where timelines are already under pressure, small structural changes can make a material difference to delivery. If these are challenges your team is currently facing, get in touch to discuss how others are approaching them in practice.

Let us talk about what you are seeing

We support global programmes with teams in Australia, the UK and Latin America. If timelines are already under pressure, the right time to address it is now.

Talk it through with our team →

No commitment. Just a conversation.

Kwesi Ackah is Global Director of Strategic Development at My Medical Department, a physician-led medical consultancy operating across Australia, the United Kingdom and Latin America. Connect on LinkedIn · mymedicaldepartment.com

© My Medical Department 2026. Executive Briefing series.

Reflections from MAPS-MAPA Australia: People, Partnerships and the Future of Medical Affairs

Newsletter

The MAPS-MAPA Australia meeting is always a highlight on the calendar, a chance to connect with peers, share ideas and explore how our field continues to evolve. This year was no different. Over the course of the event, our team at My Medical Department (MMD) had the privilege of engaging in some fantastic conversations about the role of innovation, collaboration and technology in shaping the future of medical affairs.

Who We Are and Why We’re Here

As a physician-led, global medical consultancy, My Medical Department (MMD) brings together doctors, pharmacists and scientists across Australia, the UK and Latin America. We provide on-demand medical department functions tailored to organisations of all sizes. Whether it’s medical affairs, regulatory support, pharmacovigilance or medical writing. Our focus is always the same: keeping patients at the centre and delivering safe, scientifically robust solutions.

Being at MAPS-MAPA gave us the opportunity not only to share what we do, but also to listen and learn from others in the community. That exchange of perspectives from colleagues, partners and industry leaders is what makes these events so valuable

Talking AI: Excitement and Responsibility

One of the big topics this year was, unsurprisingly, artificial intelligence. Across the sessions and in countless hallway conversations, people were asking: How do we use AI to make our work better, without losing the human touch?

We’ve seen first-hand how tools like large language models can help with everything from summarising medical calls to creating patient-friendly content. They free up time and headspace so experts can focus on higher-value work. But with that opportunity comes responsibility. Bias, governance and the need for humans to remain firmly “in the loop” were recurring themes and ones we strongly believe in.

Partnering to Shape the Future of AI in Medical Affairs

At MMD, we’re committed to exploring AI responsibly and practically. That means not just adopting tools, but actively partnering with AI providers to test, refine, and validate their solutions in real-world medical affairs contexts.

By working alongside innovators, we help ensure these technologies are safe, compliant, and genuinely useful for the professionals who will rely on them. It’s about blending our physician-led expertise with emerging AI capabilities — ensuring that progress in this space is both exciting and responsible.

At MAPS-MAPA, the conversations we had reinforced just how important this role is. There’s a real appetite across the industry to harness AI, but also a recognition that it must be done with care. Being part of that journey, alongside trusted partners, is something we’re incredibly proud of.

Photo 3
Shared Image (10)
Photo 6
Photo 5
Photo 4
Photo 2

Looking Ahead

As we reflect on MAPS-MAPA Australia, what stands out most are the people: the colleagues we reconnected with, the new relationships we formed and the energy in the room when passionate professionals come together to talk about the future.

AI will undoubtedly become a standard part of how medical affairs teams work. But the real differentiator will be how we as people adopt it, shape it and use it to better serve patients. That’s the future we want to help build at My Medical Department: combining our global expertise, innovative partnerships and patient-first values to support organisations every step of the way.

To everyone who stopped by to talk with us at MAPS-MAPA and enjoyed our cupcakes: thank you. We left inspired, motivated and more convinced than ever that together, we’re shaping a better future for medical affairs.

👉 If you’d like to explore how we can support your organisation, whether through medical affairs expertise, regulatory guidance or responsible adoption of AI. We’d love to start a conversation. Get in touch with us here.

📩 Email us at enquiries@mymedicaldepartment.com
🌐 Visit www.mymedicaldepartment.com

Pharmaceutical Medical Expertise. Anytime. Anywhere.

    The Crucial Role of Final Signatories in the Pharmaceutical Industry (UK)

    My Medical Department Strategy Consulting

    Final signatories are crucial in markets operating under strict regulatory frameworks.

    The pharmaceutical industry operates under strict regulatory frameworks to ensure that medicines and healthcare products meet the highest standards of safety, efficacy, and compliance. One key role in maintaining these standards is that of the final signatory, a professional who bears the ultimate responsibility for approving promotional materials, ensuring compliance with industry regulations, and safeguarding public health. However, final signatories constantly face competing interests that make their role uniquely challenging.

    The Balancing Act of Final Signatories.

    While final signatories are required to apply the strictest possible compliance standards, they are also frequently challenged by:

    1. Brand Messaging vs. Compliance – Companies push for the strongest possible messaging to differentiate their brands, but signatories must ensure this remains within legal and ethical boundaries.
    2. International Regulatory Variability – Messaging consistency across different countries is difficult when regulations vary widely. The UK is often perceived as one of the most restrictive environments, making global alignment a challenge.
    3. Rapidly Advancing Technology – Innovations like AI chatbots for answering customer queries evolve faster than regulations can keep up, leaving signatories navigating grey areas in compliance.
    4. Social Media Complexities – Companies seek engagement on platforms like LinkedIn, but social media interactions can inadvertently breach regulations. A significant number of complaints under industry codes arise from company personnel liking or reposting company announcements on publicly visible media.

    Interpretation and Inconsistencies in Compliance.

    The regulatory code is open to interpretation, and rulings by the Prescription Medicines Code of Practice Authority (PMCPA) can evolve and sometimes be inconsistent. This means that no two final signatories will necessarily assess a compliance challenge in exactly the same way, leading to frustration for companies that receive differing advice on similar issues.

    The Multifaceted Expertise Required.

    Final signatories must strike a balance between medical expertise, keeping up to date with the latest data and scientific advancements and skills typically associated with the legal profession. Unlike in the US, where compliance is managed through a Medical, Legal, and Regulatory (MLR) process, the UK often expects final signatories to perform all three functions themselves, adding to the role’s complexity.

    The Importance of Support and Collaboration.

    New final signatories need strong support to navigate these challenges effectively. This includes:

    • Guidance from experienced colleagues to help interpret complex and evolving regulations.
    • A robust compliance team to provide additional oversight and support.
    • Close cooperation with commercial and marketing colleagues to ensure that promotional materials are both impactful and compliant.
    • Alignment with international teams to manage regulatory variations while maintaining a consistent global brand presence.

    Final signatories play an indispensable role in the pharmaceutical industry, balancing strict compliance with the evolving demands of marketing, technology, and international regulations. Their role requires a unique blend of medical, legal, and regulatory expertise, making collaboration and ongoing education essential. As the industry continues to evolve, the challenges faced by final signatories will only grow, reinforcing their critical position as guardians of responsible pharmaceutical communications.

    If you would like to speak with our Final Signatory team to learn more or discuss your compliance needs, please get in touch with us today.